Literature DB >> 7214299

Urothelial susceptibility to tumor cell implantation: influence of cauterization.

M S Soloway, S Masters.   

Abstract

In an effort to determine whether transitional tumor cells will preferentially implant on the cauterized urothelial surface, a reproducible technique for cauterization of a portion of the murine bladder was established. This technique simulated a transurethral fulguration of a bladder tumor in humans. Transplantable tumor cells (1 X 10(6)) were placed transurethrally into the bladder of 50 mice. Twenty-five of these mice each had a portion of their bladder cauterized prior to insertion of tumor cells. Implantation with subsequent tumors occurred in 54% of mice with cauterization, in contrast to 12% of mice with an intact urothelial surface (P less than 0.005). Intravesical thio-tepa, mitomycin C, and cis-platinum were capable of significantly reducing the incidence of implantation. These results suggest that seeding may be a contributing factor to the high recurrence rate following endoscopic resection or fulguration of bladder tumors and that intravesical chemotherapy initiated shortly after surgery may reduce the incidence of implantation.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7214299     DOI: 10.1002/1097-0142(19800901)46:5<1158::aid-cncr2820460514>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Analysis of tissue ABH antigens in superficial bladder tumours.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

2.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 3.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

Review 4.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  [Early instillation in superficial bladder carcinoma. Current status].

Authors:  S Langbein; A Häcker; J K Badawi; M S Michel; P Alken
Journal:  Urologe A       Date:  2004-12       Impact factor: 0.639

Review 6.  Expectant Management of Low-Risk Bladder Cancer.

Authors:  Zachary L Smith; Mark S Soloway
Journal:  Curr Urol Rep       Date:  2015-12       Impact factor: 3.092

7.  Clinical significance of random bladder biopsy in primary T1 bladder cancer.

Authors:  Masafumi Otsuka; Satoru Taguchi; Tohru Nakagawa; Teppei Morikawa; Shigekatsu Maekawa; Jimpei Miyakawa; Akihiko Matsumoto; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma
Journal:  Mol Clin Oncol       Date:  2018-03-08

8.  The efficacy and safety of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms.

Authors:  Zhaoyi Li; Ruipeng Hou; Jian Li
Journal:  Int Urol Nephrol       Date:  2013-10-05       Impact factor: 2.370

9.  Species differences in regenerative hyperplasia of bladder urothelium after transurethral cauterization.

Authors:  H Akaza; K Koseki; T Niijima
Journal:  Urol Res       Date:  1986

10.  Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study.

Authors:  Masashi Matsushima; Eiji Kikuchi; Masanori Hasegawa; Kazuhiro Matsumoto; Akira Miyajima; Mototsugu Oya
Journal:  BMC Urol       Date:  2010-06-30       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.